Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact Limited reported that its SVP and Chief Legal Officer, Sydney Schaub, received an award of 63,357 common shares in the form of unvested restricted share units on 01/06/2026 at a grant price of $0 per share. Each RSU represents the right to receive one Genpact common share upon vesting. One-third of the shares underlying this RSU award will vest on each of December 8, 2026, December 8, 2027 and December 8, 2028, as long as Schaub continues in service through each vesting date. Following this grant, Schaub beneficially owned 63,357 common shares directly.
Genpact Limited reported an insider equity award to its President and CEO, who is also a director. On December 17, 2025, the executive received 125,130 restricted share units (RSUs) of Genpact common shares at a price of $0 per share, granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share when it vests.
One-third of the shares underlying this RSU award will vest on each of December 17, 2026, December 17, 2027 and December 17, 2028, contingent on the executive’s continued service through each vesting date. After this transaction, the executive beneficially owns 420,376 Genpact common shares directly.
Genpact LTD disclosed an insider ownership report for one of its senior executives. The filing relates to Sydney Schaub, who serves as SVP and Chief Legal Officer, with an event date of 12/08/2025.
According to the filing, no Genpact securities are beneficially owned, as noted in the explanation of responses. The form is filed for a single reporting person and is signed by Thomas D. Scholtes as attorney-in-fact for Sydney Schaub under a referenced power of attorney (Exhibit 24.1).
Genpact Limited announced that its subsidiaries Genpact UK Finco plc and Genpact USA, Inc. completed a public Notes Offering of
Genpact intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming its existing 1.750% senior notes due
Genpact Ltd (G) reported that its Chief Financial Officer filed a Form 4 disclosing an open-market sale of company stock. On 11/14/2025, the CFO sold 13,365 common shares of Genpact at a weighted average price of $44.84 per share, with individual sale prices ranging from $44.81 to $44.89. Following this transaction, the reporting person beneficially owns 148,026 Genpact common shares. This total includes 1,358 shares held under the Genpact Employee Stock Purchase Plan, of which 169 shares were acquired under the plan since a prior report filed on March 13, 2025.
Genpact UK Finco plc and Genpact USA, Inc. priced a $350,000,000 offering of 4.950% Senior Notes due 2030, fully and unconditionally guaranteed on a senior unsecured basis by Genpact Limited and Genpact Luxembourg S.à r.l. The notes mature on November 18, 2030 and pay interest semi-annually on May 18 and November 18, starting May 18, 2026.
The notes were offered at 99.593% with a 0.400% underwriting discount, resulting in proceeds before expenses of $347,175,500; Genpact estimates net proceeds of approximately $345.4 million. The company intends to use the net proceeds for general corporate purposes, which may include repaying or redeeming the 1.750% Senior Notes due 2026, of which approximately $350 million is outstanding, at or prior to their April 10, 2026 maturity.
The notes are senior unsecured obligations with optional redemption at a make‑whole premium before October 18, 2030 and at par thereafter, and include a change of control repurchase at 101% of principal. Genpact plans to apply to list the notes on The International Stock Exchange; there is currently no public market.
Form 144 filing: A holder notified intent to sell up to 13,365 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/14/2025. The filing lists an aggregate market value of $599,314.67 for the planned sale.
The shares were acquired as restricted stock from the issuer on 08/02/2022. As context, 172,414,423 shares were outstanding at the time referenced.
Genpact (G) reported insider transactions by its SVP & Chief Legal Officer. On 11/11/2025, the officer sold 1,039 common shares at $44.02. On 11/12/2025 and 11/13/2025, the officer exercised employee stock options at $27.7 for 4,351 and 45,703 shares, respectively, and sold the corresponding shares at $45.74. Following these transactions, the officer directly beneficially owned 50,569 common shares. The reported option grant was scheduled to expire on 01/09/2029 and vested 50% on January 10, 2022 and 50% on January 10, 2024.
Genpact Ltd (G) — Form 4 insider transaction: Senior Vice President Sameer Dewan reported a sale of 26,531 common shares on 11/11/2025, coded “S” for sale. The weighted average price was $44.7, with disclosed trade prices ranging from $44.70 to $44.7305.
Following the transaction, Dewan beneficially owns 62,617 shares, held directly.
Genpact Ltd (G) director Tamara Franklin reported a sale of 2,750 common shares at $45.65 on November 12, 2025, according to a Form 4 filing. Following the transaction, she beneficially owns 22,236 shares, held directly. The filing lists a transaction code “S,” indicating a sale, and shows no derivative securities activity reported.